Carbonic anhydrase IX as a novel candidate in liquid biopsy

Ozen Ozensoy Guler,Claudiu. T. Supuran,Clemente Capasso
DOI: https://doi.org/10.1080/14756366.2019.1697251
2019-12-02
Journal of Enzyme Inhibition and Medicinal Chemistry
Abstract:<span>Among the diagnostic techniques for the identification of tumour biomarkers, the liquid biopsy is considered one that offers future research on precision diagnosis and treatment of tumours in a non-invasive manner. The approach consists of isolating tumor-derived components, such as circulating tumour cells (CTC), tumour cell-free DNA (ctDNA), and extracellular vesicles (EVs), from the patient peripheral blood fluids. These elements constitute a source of genomic and proteomic information for cancer treatment. Within the tumour-derived components of the body fluids, the enzyme indicated with the acronym CA IX and belonging to the superfamily of carbonic anhydrases (CA, EC 4.2.1.1) is a promising aspirant for checking tumours. CA IX is a transmembrane-CA isoform that is strongly overexpressed in many cancers being not much diffused in healthy tissues except the gastrointestinal tract. Here, it is summarised the role of CA IX as tumour-associated protein and its putative relationship in liquid biopsyfor diagnosing and monitoring cancer progression.</span>
biochemistry & molecular biology,chemistry, medicinal
What problem does this paper attempt to address?